Convert Pharmaceuticals is a pioneering platform company specializing in the development of prodrugs that remain inert until they reach the tumor site. These innovative drugs then transform into powerful anti-cancer agents within the tumor microenvironment. Leveraging proprietary insights into tumor biology and specific biomarkers, Convert Pharmaceuticals meticulously designs prodrugs to specifically target tumor hypoxia, a major contributor to cancer treatment resistance.
Tumor hypoxia is a common characteristic found in approximately 50% of solid tumors. Through our cutting-edge development of two key biomarkers, we have discovered that certain cancer types are particularly responsive to our therapies. These include pancreatic cancer, ovarian cancer, breast cancer, prostate cancer, and head and neck squamous cell carcinoma, positioning our treatments at the forefront of combating these challenging diseases.
Convert Pharmaceuticals, a leader in developing innovative therapies for treatment-resistant cancers, is pleased to announce its recent achievement of being awarded the prestigious and highly competitive EIC Accelerator grant under Horizon Europe. Convert Pharmaceuticals has earned a reputation for its groundbreaking work in developing Hypoxia-Activated Prodrugs......
Several academic centers have collaborated with Convert Pharmaceuticals to expand knowledge about its main compound, CP-506, and the biomarkers that will enable selection of patients that would most benefit from the hypoxia activated prodrug under investigation. These research efforts have recently led to three key......
We are glad to share that the Clinical Trial Application prepared by Convert Pharmaceuticals for the Phase 1 Clinical Trial of CP-506 (NCT04954599) has been approved by both the Competent Authorities and the reference Ethical Committee in the Netherlands. The prodrug will be tested in......